Public Company List
| Ticker | Company | Lead Asset | Indication | Stage | Next Catalyst |
|---|---|---|---|---|---|
| TSHA | Taysha Gene Therapies | TSHA-102 | Rett Syndrome | Phase 3 | 2027-03-12 |
| TELO | Telomir Pharmaceuticals Inc | Targeting Metal-Dependent Epigenetic Dysregulation | n/a | n/a | 2027-05 |
| PASG | Passage Bio Inc | PBFT02 | n/a | Phase 1/2 | 2030-11-01 |
| LGVN | Longeveron Inc | Allogeneic MSC | Mild Alzheimer's Disease | Phase 2 | Corporate Update |
| MTNB | Matinas Biopharma Holdings Inc | MAT2203 | general corporate purposes | Phase 3 | Data Readout |